Loading organizations...

§ Private Profile · South San Francisco, CA, USA
Cloud bioreactor services for biotech and cellular agriculture firms. Grow cells, develop processes, and analyze data with bioprocessing.
Culture Biosciences has raised $106.6M across 5 funding rounds.
Key people at Culture Biosciences.
Culture Biosciences was founded in 2016 by Matt Ball (Founder/CTO) and Will Patrick (Founder/CEO).
Culture Biosciences has raised $106.6M in total across 5 funding rounds.
Culture Biosciences is a South San Francisco, California-based company that provides cloud-based bioprocessing infrastructure and automated bioreactor services to the biotechnology industry. The organization enables customers to remotely execute cell culture experiments, optimize manufacturing processes, and analyze biological data through proprietary software systems. Operating on a pay-per-use model, the platform serves clients working across cellular agriculture and biopharma who genetically modify organisms to produce therapeutics, materials, fuels, and foods. The enterprise currently maintains a workforce of approximately 40 employees and recently secured $80 million in Series B financing to scale its cloud bioreactor facility. The company has received financial backing from prominent venture capital firms and startup accelerators, including recognizable investors such as Y Combinator, Northpond Ventures, and Synthesis Capital. Culture Biosciences was officially established in 2016 by co-founders Will Patrick and Matt Ball.
Key people at Culture Biosciences.
Culture Biosciences is a biotech company that provides cloud-connected bioreactor technology and bioprocess development services to biotech and biopharma companies. They enable clients to accelerate cell culture process development for gene and protein therapies by remotely designing, running, and analyzing experiments through their proprietary software platform, Console. Their offering helps biotech companies optimize bioprocesses faster and more efficiently, reducing time to market for therapeutics, synthetic biology products, and other biologics[1][2][3][4].
Founded in 2016 by Will Patrick (Founder/CEO) and Matt Ball (Founder/CTO), Culture Biosciences emerged from the founders’ backgrounds in biology, engineering, and robotics. They identified a bottleneck in bioprocess development where companies lacked scalable, flexible, and data-driven tools to optimize cell culture experiments. Early traction came from building cloud-native bioreactors and software that allowed remote experiment management, which attracted over 70 biotech clients and significant venture funding, including an $80M Series B round in 2021[2][4].
Culture Biosciences rides the wave of digital transformation in biomanufacturing, leveraging cloud computing, automation, and data science to modernize upstream bioprocess development. The timing is critical as biotech companies face increasing pressure to accelerate therapeutic development and reduce costs. Market forces such as the growth of gene and protein therapies, synthetic biology, and cellular agriculture favor solutions that enable rapid, reproducible, and scalable bioprocess optimization. Culture’s platform influences the ecosystem by democratizing access to advanced bioprocessing tools, fostering innovation, and enabling startups to compete more effectively[1][2][3][4].
Looking ahead, Culture Biosciences is poised to expand its modular bioreactor offerings and software capabilities, including the upcoming Stratyx 250™ system and partnerships like the one with Cytiva to enhance scale-up confidence. Trends such as AI/ML integration in bioprocess analytics, increased demand for sustainable biologics, and cloud-based R&D workflows will shape their growth. Their influence is likely to deepen as they continue to lower barriers for biotech innovation, making bioprocess development as fast and easy as scaling software, ultimately accelerating the delivery of new therapies and biologics to market[3][5][6].
Culture Biosciences has raised $106.6M across 5 funding rounds. Most recently, it raised $80.0M Series B in October 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2021 | $80M Series B | Northpond Ventures | Better Ventures, Playground Global, Sandbox Industries, Tencent Holdings, BoxGroup, Craft Ventures, Cultivian Sandbox Ventures, E14 Fund, Section 32, Synthesis Capital, The Production Board, Verily | Announced |
| Mar 1, 2020 | $15M Series A | DAN Phillips | Sandbox Industries, E14 Fund, Section 32, David Friedberg, Verily, Y Combinator | Announced |
| Feb 12, 2019 | $5.5M Venture Round | — | BoxGroup, Data Collective, Refactor Capital, Bill Maris, Verily, Y Combinator | Announced |
| Feb 1, 2019 | $6M Series U | — | Andreessen Horowitz, Arthur Ventures, Benchmark, Compound, Refactor Capital, Adam Lisagor | Announced |
| Jan 1, 2018 | $120K Seed | — | Bluestein Ventures, Goat Capital, KIN Ventures, Prochain Ventures, Schematic Ventures, Seven Seven SIX, UpHonest Capital, Y Combinator, Chris Fanini, Elizabeth Iorns, Emmett Shear | Announced |
Culture Biosciences was founded in 2016 by Matt Ball (Founder/CTO) and Will Patrick (Founder/CEO).
Culture Biosciences has raised $106.6M in total across 5 funding rounds.
Culture Biosciences's investors include Northpond Ventures, Better Ventures, Playground Global, Sandbox Industries, Tencent Holdings, BoxGroup, Craft Ventures, Cultivian Sandbox Ventures, E14 Fund, Section 32, Synthesis Capital, The Production Board.